Thus, immune checkpoint inhibitors (ICIs) have rapidly progressed in the treatment of HCC, but monotherapy with programmed cell death protein-1 (PD-1) antibody only caused tumor regression in 20% of the patients. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.